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Functional Screening of Alzheimer Pathology
Genome-wide Association Signals in Drosophila
Joshua M. Shulman,1,2,3 Portia Chipendo,1,2,3 Lori B. Chibnik,1,2,3 Cristin Aubin,1,2,3 Dong Tran,1,2,3
Brendan T. Keenan,1,2,3 Patricia L. Kramer,4 Julie A. Schneider,5,6 David A. Bennett,6 Mel B. Feany,2,7,9,*
and Philip L. De Jager1,2,3,8,9,*
We have leveraged a Drosophilamodel relevant to Alzheimer disease (AD) for functional screening of findings from a genome-wide scan
for loci associated with a quantitative measure of AD pathology in humans. In six of the 15 genomic regions evaluated, we successfully
identified a causal gene for the association, on the basis of in vivo interactions with the neurotoxicity of Tau, which forms neurofibrillary
tangles in AD. Among the top results, rs10845990 within SLC2A14, encoding a glucose transporter, showed evidence of replication for
association with AD pathology, and gain and loss of function in glut1, the Drosophila ortholog, was associated with suppression and
enhancement of Tau toxicity, respectively. Our strategy of coupling genome-wide association in humans with functional screening
in a model organism is likely to be a powerful approach for gene discovery in AD and other complex genetic disorders.Genome-wide association studies (GWAS) have emerged as
powerful tools for the dissection of complex genetic traits,
such as susceptibility to Alzheimer disease (AD, MIM
104300);1 however, efficient methods are needed to
enhance follow-up of association signals in order to accel-
erate the identification and functional validation of genes
affected by causal variants.2 On the basis of recent anal-
yses, the top of GWAS-results distributions (103 < p <
107), though falling short of genome-wide significance
(p < 5 3 108), are likely enriched for true associations,
but these signals are obscured by a substantial number of
chance observations with comparable statistical
evidence.3–5 New strategies are therefore needed, not
only to validate associations with the best evidence, but
also to facilitate identification of true signals of association
in circumstances where statistical power is limited and
increased sample size is not feasible. One potential solu-
tion is to couple the GWAS with a functional screen that
evaluates candidate genes for participation in a relevant
pathological cascade, a two-stage strategy that might effec-
tively increase overall study power. Here, we leverage
a model system relevant to AD in the fruit fly, Drosophila
melanogaster, to perform functional testing of 19 genes
from 15 distinct genomic regions identified in a GWAS
for loci influencing the burden of AD pathology in
humans.
AD is the most common cause of dementia, and it is
characterized at autopsy by widespread neuronal loss in
association with extracellular amyloid plaques and intra-
cellular neurofibrillary tangles, predominantly comprising
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found to influence susceptibility for AD, and GWAS have
recently been successful at discovering such loci.1,7–9
Most GWAS conducted to date have relied on the dichoto-
mous outcome of AD clinical diagnosis; however, this
study design is potentially confounded by genetic hetero-
geneity of dementia in cases and subclinical disease in
controls. In a complementary approach, we have based
our analysis on a relevant AD intermediate phenotype:
a quantitative measure of global AD pathology from post-
mortem counts of amyloid plaques and neurofibrillary
tangles. Although this approach potentially offers more
statistical power than a case-control study of comparable
size,10,11 it is limited by the difficulty in obtaining neuro-
pathologic data on large numbers of older individuals.
Thus, we anticipated a challenge in meeting the statistical
burden of proof for gene discovery, and therefore we
coupled our association analysis with a functional
screening paradigm in order to validate our results.
A GWAS was performed in an autopsy cohort consisting
of 227 participants from the Religious Orders Study and
the Rush Memory and Aging Project, two longitudinal,
epidemiologic studies of aging and AD that include brain
donation at death.12–14 Written informed consent was
given and an Anatomic Gift Act signed by all study partic-
ipants after the procedures were fully explained, and both
studies were approved by the institutional review board of
Rush University Medical Center. Subjects were nonde-
mented at recruitment and were followed prospectively
with annual clinical evaluations. Proximate to death,
40% of subjects had normal cognition, 22% had mild15, USA; 2Harvard Medical School, Boston, MA 02115, USA; 3Program in
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Table 1. GWAS Results and Functional Screening
SNP Locus Alleles MAF Beta (95% CI) p Value Human Gene(s)
Functional Screen
Fly Ortholog LOF GOF
rs393569 19q13 C/T 0.49 0.15 (0.09 to 0.21) 1.64 3 106 SPTBN4 B-spec Enh -
SHKBP1 CG9467 - N/A
LTBP4
rs1941526 18q12 A/G 0.28 0.15 (0.09 to 0.22) 6.46 3 106 PIK3C3 Pi3K59F - N/A
rs17468071 9p21 C/T 0.11 0.22 (0.12 to 0.31) 7.87 3 106 ELAVL2 fne Sup Enh
rs2280861 8p21 C/T 0.25 0.16 (0.23 to 0.09) 1.40 3 105 ENTPD4 NTPase - -
SLC25A37 mfrn - -
rs10065260 5q14 C/A 0.49 0.13 (0.07 to 0.19) 2.38 3 105 SCAMP1 Scamp - -
LHFPL2 CG3770 - N/A
rs1935502 10p12 A/G 0.30 0.15 (0.08 to 0.21) 2.66 3 105 SLC39A12 CG10006 - N/A
rs3824982 11p14 T/C 0.22 0.15 (0.08 to 0.22) 3.22 3 105 MPPED2 CG16717 - N/A
rs12378647 9q33 G/A 0.35 0.14 (0.08 to 0.21) 3.44 3 105 DBC1
rs16898 5q14 T/C 0.31 0.13 (0.19 to 0.07) 4.64 3 105 HAPLN1
rs2108720 7p14 T/C 0.22 0.16 (0.23 to 0.08) 5.23 3 105 POU6F2 pdm3 - N/A
rs527346 12p13 G/A 0.45 0.12 (0.18 to 0.06) 5.72 3 105 TSPAN9 tsp5D - N/A
rs10845990 12p13 T/G 0.39 0.13 (0.06 to 0.19) 6.93 3 105 SLC2A14 Glut1 Enh Sup
NANOG bsh - -
rs9513122 13q32 G/A 0.43 0.12 (0.18 to 0.06) 1.70 3 104 HS6ST3 hs6st Enh -
rs7591708 2p15 T/C 0.35 0.12 (0.06 to 0.18) 1.93 3 104 EHBP1 CG15609 - N/A
rs7128063 11q14 A/G 0.25 0.13 (0.20 to 0.06) 5.93 3 104 DLG2 dlg Enh -
rs12634690 3p12 T/C 0.33 0.11 (0.17 to 0.04) 1.32 3 103 ROBO2 robo - -
rs297808 5q35 G/A 0.36 0.09 (0.03 to 0.15) 2.60 3 103 SLIT3 slit Enh Sup
Alleles are denoted as minor/major. Beta is calculated per copy of minor allele under the additive genetic model with adjustment for age at death and APOE 34
genotype. CI, confidence interval. Functional Screen shows screening results based on testing of gain or loss of function (GOF and LOF, respectively) in orthol-
ogous fly genes for enhancement (Enh) or suppression (Sup) of Tau toxicity. MAF, minor allele frequency; -, no interaction observed; N/A, genetic reagent not
available. Fly orthologs were identified on the basis of implementation of the tBLASTn algorithm50 within the annotated Drosophila genome. All orthologs had
highly significant BLAST results: E value < 1010 and mean score ¼ 398 (range: 67–1462). Fly genes with evidence of functional interactions with Tau toxicity
are shown in boldface type.cognitive impairment, and 38%met clinical criteria for AD
(Table S1 available online). After quality control, 334,575
SNP genotypes were available for analysis (Figure S1). The
outcome was a continuous measure of global AD
pathology, based on averaged counts of neuritic plaques,
diffuse plaques, and neurofibrillary tangles on silver-
stained tissue sections from five brain regions (midfrontal,
middle temporal, inferior parietal, and entorhinal cortices
and the hippocampal CA1 sector).15,16 Linear regression
was used to evaluate SNP associations with the continuous
AD pathological trait, adjusting for both age at death and
APOE 34 (MIM 107741) genotype. The top independently
associated regions (p < 1 3 103) containing candidate
genes are presented in Table 1 (for full results, see Table
S2). Of note, the subjects in the study cohort were also
part of a larger autopsy collection used for a recent candi-
date-based analysis of associations with AD pathology
intermediate phenotypes;11 however, none of the lociThe Americaexamined in that study exceeded the significance
threshold applied here, and many of those SNPs were not
captured by the Illumina genotyping platform used in
this genome scan.
As expected for our small study, no variant achieved
genome-wide significance, and we therefore implemented
our functional screening strategy. Candidate genes in the
vicinity of top-scoring SNPs were identified on the basis
of linkage disequilibrium criteria (Table 1 and Table S2),
and in each case, all such genes were included for further
evaluation in an unbiased fashion. In nine out of 24 cases,
no candidate genes were identified in the target genomic
region around an index SNP, and these association signals
were not pursued further. We additionally chose to eval-
uate two genomic regions that were identified by SNP asso-
ciations of more modest significance but contained genes
(SLIT3 [MIM 603745] and ROBO2 [MIM 602431]) that
function as ligand and receptor, respectively, in a commonn Journal of Human Genetics 88, 232–238, February 11, 2011 233
neuronal signaling pathway. Nineteen out of the 22 candi-
date genes had conserved orthologs in Drosophila and were
promoted to functional testing.
A variety of Drosophila experimental models relevant to
AD have been developed, including transgenic systems
based on the neurotoxicity of both Aß and Tau.17–19 For
functional screening of GWAS results, we selected the Tau
transgenicmodel because (1) it has previously been success-
fully employed for rapid genetic screening20 and (2) there
is growing consensus that Tau is a downstream mediator
of Aß toxicity in AD.6,21–23 Expression of human Tau
(MAPT [MIM 157140]) in the Drosophila nervous system
recapitulates several features of AD, including age-depen-
dent neurodegeneration, decreased lifespan, and abnor-
mally phosphorylated and misfolded Tau.19 We used
transgenic animals, allowing tissue-specific expression of
TauV337M, a mutant form of Tau associated with familial
frontotemporal dementia (FTD [MIM 600274]). Impor-
tantly, wild-type and mutant forms of human Tau demon-
strate similar mechanisms of toxicity when expressed in
theDrosophilanervous systemand show consistent interac-
tions with known genetic modifiers.19,24,25 Therefore,
similar to transgenic mouse models based on FTD mutant
Tau,26,27 the fly model selected for our study is relevant to
understanding the mechanisms of Tau toxicity in AD.28
TauV337M expression in the fly eye causes a moderately
reduced eye size and roughened surface (Figure 1B), a
phenotype that is amenable to rapid screening for
second-site genetic modifiers.20 Specifically, by scoring
for lines that either exacerbate or rescue the eye pheno-
type, genes can be characterized as enhancers or suppres-
sors of Tau toxicity, respectively. For loss-of-function
analysis, transgenic RNA-interference (RNAi) lines were
tested for all 19 target genes,29,30 and classical Drosophila
mutant alleles were also available in most cases.31,32 In
addition, we evaluated lines known or predicted to activate
gene expression, allowing assessment for gain-of-function
interactions for many loci.33 Genetic modifier effects were
scored with the use of a semiquantitative rating scale of
rough-eye severity, allowing statistical comparison with
Tau transgenic controls (Figure S4).
Out of the 19 genes evaluated in the fly model, six genes
show interactions with Tau toxicity in vivo (Table 1,
Figure 1, and Figure S2), providing functional evidence
that strengthens the validity of the GWAS results. In three
notable cases, both loss- and gain-of-function experiments
demonstrate reciprocal interactions. Specifically, SLC2A14
(MIM 611039) was selected for evaluation on the basis of
an associated intronic SNP (rs10845990), and a single or-
tholog (glut1) is present in the Drosophila genome.34 A
line predicted to increase glut1 expression was a potent
Tau suppressor, restoring the eye to nearly wild-type
appearance (Figure 1C), and a glut1 RNAi line had the
opposite effect, enhancing Tau toxicity and leading to
a worsened eye phenotype (Figure 1F). Similarly, SLIT3
was selected for testing on the basis of an intronic SNP,
rs297808. Increasing expression of the orthologous fly234 The American Journal of Human Genetics 88, 232–238, Februarygene, slit, rescues the Tau-induced eye phenotype (Fig-
ure 1D), whereas slit RNAi increases Tau toxicity (Fig-
ure 1G). In addition, we find evidence to support func-
tional validation of ELAVL2 (MIM 601673), a gene found
in the vicinity of rs17468071. Transgene-mediated expres-
sion of found in neurons (fne), an ortholog of ELAVL2,
strongly increased Tau toxicity in the fly eye (Figure 1H),
and at higher levels, fne caused pupal lethality when coex-
pressed with Tau. Reciprocally, an fne RNAi line attenuated
Tau toxicity (Figure 1E). The Drosophila genome contains
two other ELAVL2 orthologs, including the founding
family member, elav, and Rbp9; however, manipulating
the expression of these genes in the absence of Tau was
associated with substantial toxicity, limiting further evalu-
ation using our screening strategy. Finally, RNAi directed
against three other fly genes, b-spectrin, heparan sulfate
6-O-sulfotransferase, and discs large 1, each enhance Tau
toxicity, supporting functional validation of the ortholo-
gous loci implicated by our GWAS (Table 1 and Figure S2).
For the six loci highlighted by the Drosophila functional
screen, we genotyped the index SNP in an additional 305
deceased study participants with completed neuropatho-
logical evaluation (Table S3). rs10845990, within the
SLC2A14 locus, showed suggestive evidence of replication
(p ¼ 0.03), and the association was improved in a pooled
analysis of 532 subjects, including both the discovery
and the replication cohorts (pDISC ¼ 6.9 3 105, pJOINT ¼
8.1 3 106). SLC2A14, encoding a glucose transporter
(GLUT14), is an attractive biological candidate given the
well-known dysregulation of glucose metabolism in the
AD brain and likely pathogenic role of oxidative stress.6
Although predominantly expressed in the testes,35 less
abundant SLC2A14 transcripts are also detected in the
central nervous system, on the basis of publically available
transcriptome data (see Web Resources).36–38 Glucose
transporter expression has been reported to be reduced in
brains affected by AD, correlated with both Tau phosphor-
ylation and neurofibrillary tangle burden.39 Interestingly,
genetic and pharmacological manipulation of oxidative
stress has previously been shown to modulate Tau-induced
toxicity in flies,40 potentially consistent with this mecha-
nism of action for the observed interaction with glut1.
In summary, on the basis of genetic association in hu-
mans and functional screening in a pertinent model
organism, we have identified six candidate loci that influ-
ence the accumulation of AD neuropathology. Our
strategy of integrating human GWAS with a Drosophila
genetic screen builds on similar successful cross-species
studies in which fly models of neurodegenerative disease
enabled secondary screens to reinforce findings from
mammalian systems, including transcriptome analysis41
and drug discovery.42 The Drosophila Tau transgenic model
selected for our functional screening pipeline has been
used in prior successful genetic screens and numerous
other investigations,20,24,25,43 and many results have
been consistent with findings in mouse models and other
AD experimental paradigms.28,44 In current hypotheses11, 2011
Figure 1. Functional Screening of GWAS Results, Based on Interactions of Gene Orthologs with Tau Toxicity In Vivo
Compared to control animals (A, GMR-Gal4/þ), expression of human Tau generates a reduced eye size and moderate roughened appear-
ance (B, UAS-TauV337M/þ; GMR-Gal4/þ).19 Lines predicted to increase the expression of glut1 (C, UAS-TauV337M/þ; GMR-Gal4/þ;
Glut1d05758/þ)33 and slit (D, UAS-TauV337M/þ; GMR-Gal4/þ;UAS-sli.B/þ)47 or RNAi directed against fne (E, UAS-TauV337M/þ; GMR-Gal4/
UAS-fne.IR.v101508) suppressed Tau toxicity, restoring a near-wild-type eye. Reciprocally, RNAi directed against glut1 (F, UAS-
TauV337M/þ; GMR-Gal4,UAS-Dcr2/UAS-glut1.IR.v13326) and slit (G, UAS-TauV337M/þ; GMR-Gal4,UAS-Dcr2/UAS-slit.IR.v38233) or
increasing expression of fne (H, UAS-TauV337M/þ; GMR-Gal4/þ;UAS-fne.4-10B/þ)48 enhanced Tau toxicity, exacerbating the rough-eye
phenotype. Spatially and temporally defined expression of the yeast GAL4 transcription factor within the Drosophila retina, via the
GMR-GAL4 driver line, directs Tau transgene expression from upstream activating sequence (UAS) sites. In the case of activating gain-
of-function and RNAi lines for candidate genes, coexpression is also directed to the eye via the GAL4/UAS system.49 All photographed
animals are female so as to facilitate comparisons, but consistent modifier effects were observed in both sexes. All crosses used a w1118
genetic background and were conducted at 25C, with the exception of UAS-fne.4-10B, which was lethal in combination with UAS-
TauV337M at this temperature andwas therefore tested at 23C. All genetic enhancer lines were also tested in the absence of Tau to confirm
that there was no significant toxicity in isolation (Figure S3). Immunoblot analysis was performed to confirm that reagents identified as
modifiers of the Tau eye phenotype did not alter Tau expression levels. All genetic modifier effects were scored with the use of a semi-
quantitative scale and were shown to be significantly different (p < 0.0001) from Tau controls (Figure S4).about the mechanisms of AD pathogenesis, supported by
a large body of work, Tau-induced neurotoxicity defines a
key pathway mediating the effects of Aß.6,21–23 Therefore,
our functional screen may be relevant to many suscepti-
bility loci that influence downstream mechanisms of AßThe Americatoxicity. Nevertheless, our approach would not be ex-
pected to detect genes that directly influence the process-
ing of amyloid precursor protein (APP), Aß aggregation,
or other proximal events in the pathologic cascade. In
the future, such loci might be functionally screened withn Journal of Human Genetics 88, 232–238, February 11, 2011 235
the use of either APP or Aß transgenic flies or Aß/Tau dual
transgenic flies.17,24,45
Additional strengths of our approach include the
substantial genomic conservation between flies and
mammals46 and the availability of reagents to manipulate
the function of nearly all Drosophila genes.31 The success
rate of our strategy exceeds the returns of unbiased
Drosophila genetic screens using the same transgenic
model,20 suggesting that the list of 19 loci tested was en-
riched for genes influencing the development of AD
pathology. Although a negative result in our screen does
not exclude a gene as potentially associated with AD, the
six validated loci highlight pathways of potential relevance
to disease pathogenesis. Future functional investigation in
Drosophila, and in other experimental systems, may reveal
the mechanisms by which these genes modulate Tau-
induced neurodegeneration, and these loci are also excel-
lent targets for further replication analysis in human
cohorts. Importantly, our functional screening strategy
highlights genes that are likely responsible for association
signals, and in two cases, rs393569 and rs10845990, we are
able to nominate causal genes (SPTBN4 and SLC2A14,
respectively) for which more than one candidate was
initially found on the basis of linkage disequilibrium
with the index SNP, a commonly encountered problem
in following up GWAS results.
The association signals uncovered in our GWAS are
comparable to that of numerous published reports in larger
case-control cohorts that have identified candidate risk
loci with suggestive but not definitive statistical evidence
of association to AD or other relevant intermediate traits.1
Evidence is emerging in support of a polygenic model of
inheritance for complex genetic disorders, particularly
neuropsychiatric diseases, inwhichhundreds or even thou-
sands of commonvariants collectively contribute to disease
risk.3–5 Given the very small effect sizes, it is unrealistic that
the majority of such loci can be validated individually by
statistical evidence alone. Our strategy of coupling GWAS
in humans to functional genetic screening in a model
organism will therefore likely be a powerful strategy for
follow-up of such signals in the future for the prioritization
of genes and pathways for further investigation.Supplemental Data
Supplemental Data include four figures and three tables and can
be found with this article online at http://www.cell.com/AJHG.Acknowledgments
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